Blog

ISTANBUL, TR / ACCESS Newswire / June 30, 2025 / Aesthetic operations significantly influence self-confidence and quality of life in today’s environment, when beauty is increasingly individual and comprehensive. Doku Clinic, located in the center of Istanbul, is one of the top institutes in this discipline. The clinic has grown in popularity among patients from all over the world who are looking for exceptional outcomes in body and nose aesthetics because to its skilled staff, cutting-edge equipment, and personalized approach.

Why is Doku Clinic So Popular?

The world-renown of Doku Clinic is due to the direction of two famous doctors:

• Dr. Engin Öcal is a renowned specialist in cosmetic and plastic surgery, particularly in the areas of body contouring and breast augmentation.

• Dr. Serhan Derin is an expert in rhinoplasty surgery and finds the sweet spot between the nose’s aesthetics and its functionality.

The individualized care that patients receive at Doku Clinic is what makes it stand out. Anatomical details, skin type, and aesthetic objectives inform the development of individualized treatment programs for each patient. Every time, you can count on enduring, harmonic, and all-natural results.

Dr. Engin Öcal: A Master of Precision in Shaping Beauty

Breast augmentation, liposuction, stomach tucks (abdominoplasty), and Brazilian butt lifts (BBLs) are just a few of the popular cosmetic operations that improve patients’ physical appearance and sense of self-worth.

With each metamorphosis, Dr. Engin Öcal infuses a creative vision with therapeutic accuracy. Patients who want a natural look that complements their body proportions have come to trust Doku Clinic because of his approach to breast augmentation Turkey.

To guarantee maximum satisfaction, minimal scarring, and quick recovery, Dr. Öcal takes into account each patient’s unique anatomy and lifestyle when choosing implant size, shape, and placement. Restoring one’s femininity and self-esteem are important goals for many people undergoing the operation.

Dr. Serhan Derin’s Functional Beauty Program

Rhinoplasty, which aims to restore nasal airflow while simultaneously improving the patient’s face features, is one of the most intricate and life-altering cosmetic procedures. Renowned for his skill in customizing each nose surgery to match each patient’s unique face anatomy and medical requirements, Dr. Serhan Derin is a frontrunner in this profession.

No matter the kind of rhinoplasty-primary, revision, or ethnic-Dr. Derin always aims to create delicate, natural-looking noses that complement the patient’s overall characteristics. Simultaneously, he fixes any respiratory problems, which greatly enhances quality of life.

His dedication to natural aesthetics and individualized care is right on trend with the current movement away from “overdone” outcomes and toward embracing one’s own unique beauty.

What Made Amanda Du Pont, Alessia Spagnulo, and Priscila Da Silva Choose Doku Clinic for Their Breast Aesthetics? A Global Trust-Building Story

The worldwide influencers who candidly document their beauty adventures on social media have contributed to the growing international prominence of Doku Clinic. These women, who have millions of followers, opted for a single, game-changing operation at Doku Clinic.

Amanda Du Pont, a content producer and actress from South Africa, traveled all the way to Istanbul to have Doku Clinic implant natural breast implants. She was very complimentary of the clinic’s welcoming atmosphere, the exceptional quality of service, and the organic outcomes that Dr. Engin Öcal had accomplished. In an honest review, Amanda praised Doku Clinic and encouraged her followers to make an informed decision.

Italian fashion influencer Alessia Spagnulo has decided to have breast implants at Doku Clinic after much deliberation. Following the treatment, she enthusiastically recounted how it boosted her self-esteem and physical attractiveness. In particular, she lauded the individualized attention and the flattering effect on her figure.

In order to get a more harmonious body type, fitness and lifestyle blogger Priscila Da Silva had breast implants in Turkey. From the initial consultation before the procedure to the healing process, she wrote about how pleasant and reassuring the entire experience was. Doku Clinic, she said, “makes you feel reborn.”

Transforming Your Look Without Incisions: Experience at the Doku Clinic

For people from across the world seeking a unique medical tourism experience, Doku Clinic is more than just a place to get medical treatments done. Airport transportation, hotel stays, translation assistance, pre- and post-operative consultations, and individualized follow-ups are all part of their VIP service packages.

The cutting-edge operating rooms of Doku Clinic prioritize cleanliness and patient safety, and they have received approval from the Ministry of Health to conduct all surgical procedures. Regular check-ins and medical advice ensure that patients are properly followed throughout their recovery process.

Elegance and Self-Assurance, Harmoniously Satisfied

Restoring self-esteem and confidence are two of the many benefits of cosmetic surgery, which goes beyond only improving one’s physical look. Patients are more than simply another number at Doku Clinic; they are companions on a path to healing and personal growth.

Science, artistry, and ethical care come together at Doku Clinic, where patients may have a variety of cosmetic procedures such as breast augmentation, rhinoplasty, body contouring, and non-surgical skin treatments.

Finally, Istanbul’s Most Reliable Spot for Travelers Seeking Beauty

The cosmetic makeover you seek may begin at Doku Clinic if you are seeking natural, balanced, and long-lasting results. As a frontrunner in aesthetic innovation, the clinic has achieved global success in breast aesthetics, achieved technical mastery in nose surgery, and provides an unsurpassed patient experience.

Ready to start your aesthetic journey?

Meet Doku Clinic-where beauty and confidence meet.

Media Contact: Doku Clinic
Email: info@dokuclinic.com
Phone: +90 555 140 04 04
Website: https://www.dokuclinic.com/en
Address: Merkez Mah. İstiklal Sok. No:9 Şişli, İstanbul/Türkiye

SOURCE: Doku Clinic

View the original press release on ACCESS Newswire

By Ovais Riaz & Waa Say – Team Editorial Evrima Chicago

BIRMINGHAM, GB / ACCESS Newswire / June 30, 2025 / The Silent Crisis of Disappearing Languages

In our increasingly globalized world, UNESCO warns that nearly half of all spoken languages are currently endangered, with one disappearing every two weeks. Against this sobering backdrop, educator and author Divya Mistry-Patel has emerged as a passionate advocate for linguistic preservation through her groundbreaking work in children’s literature.

Mistry-Patel is an educator, entrepreneur, and celebrated children’s book author. She has taken a bold step toward making bilingual learning both accessible and engaging.

A Personal Journey Becomes a Cultural Mission

Born into a multicultural Gujarati family in the UK, Mistry-Patel experienced firsthand the gradual erosion of heritage languages in diaspora communities.

“I watched cousins who could understand Gujarati but couldn’t speak it, and eventually children who couldn’t even understand,” she recalls.

This personal observation sparked what would become her life’s work-creating tools to make language learning accessible, engaging, and intergenerational.

Her latest creation, Mari Rang Be Range Biladi (translated as “My Colourful Cat”), represents far more than just another bilingual picture book. It’s a comprehensive language-learning system that includes:

• Dual-language storytelling with culturally rich narratives

• Gujarati alphabet introduction with phonetic guides

• Comprehension exercises designed for family participation

• QR-code linked audiobook for proper pronunciation

• Full English translation for non-Gujarati-speaking parents

• Opportunities to see that diversity is to be celebrated and beauty is within us all

The Growing Demand for Multilingual Education

Recent studies from the University of Chicago demonstrate that bilingual children develop stronger executive function skills, showing 20% greater cognitive flexibility than monolingual peers.

Yet despite these proven benefits, the publishing industry has been slow to respond. A 2022 survey by the Cooperative Children’s Book Center revealed that while 33% of U.S. children come from bilingual homes, only 12% of children’s books published that year offered any non-English content. In the UK, around 20% of children speak or understand more than one language. Furthermore, around half of the world’s population speaks two or more languages.

Mistry-Patel has positioned herself at the forefront of changing this disparity.

“This isn’t just about language retention,” she explains. “It’s about giving children the tools to navigate their multicultural identities with confidence.”

Breaking Barriers in Publishing

The path to bringing Mari Rang Be Range Biladi to market reveals systemic challenges in the publishing industry. Major retailers often relegate bilingual books to “special interest” sections-when they carry them at all. Traditional publishers frequently reject bilingual manuscripts, citing “limited market potential.”

Yet professionals continue to emphasize the importance of encouraging parents to speak in their mother tongue with their children. Research has shown the benefits of bilingual learners, yet this is not reflected on our bookshelves.

In a world where native languages are slowly fading from everyday use, Mistry-Patel is on a mission to ensure cultural heritage and linguistic roots are preserved.

Undeterred, she adopted an innovative hybrid approach:

• Self-publishing to maintain creative control and raise awareness

• Partnering with educational institutions for distribution

• Developing teacher resources to encourage classroom adoption

• Leveraging social media to build direct community support

This strategy has yielded impressive results, with the book gaining traction in both educational circles and Gujarati communities worldwide.

Recognition and Future Horizons

The impact of Mistry-Patel’s work is gaining institutional recognition. She currently holds nominations for:

• Kent Women in Business Awards 2025 (Runner-Up in Innovation Award & Finalist in Women In Education Award)

• The Tutors’ Association Awards (Shortlisted in two categories: Education Resources for Tuition 2025 and Tuition Partner of the Year 2025)

• The Diversity Book Awards (shortlist announcement imminent)

Through her company, Academic Achievements Ltd, she is now developing versions in Punjabi, Hindi, Malayalam, and Tamil-potentially reaching over 500 million native speakers globally.

A recent partnership with local schools and Kent libraries has made the book freely available to local families, with plans for similar initiatives nationwide.

How Readers Can Support the Movement

Mistry-Patel emphasizes that preserving linguistic diversity requires a community effort:

• Request bilingual books at local bookstores and libraries

• Share experiences using #MotherTongueMatters

• Engage with content on Instagram and Facebook

• Participate in virtual reading events

• Gift bilingual books for birthdays and holidays

• Read to your children or listen to audiobooks together

The Ripple Effect of Language Preservation

As linguist Dr. Ananya Sharma notes,

“When we lose a language, we don’t just lose words-we lose entire ways of seeing the world.”

Mistry-Patel’s work represents a vital countercurrent to this loss, creating what educators are calling “the building blocks of cultural continuity.”

With Mari Rang Be Range Biladi available on Amazon and her expanding series underway, Mistry-Patel is proving that one passionate voice can indeed change the narrative-in any language.

Mistry-Patel has more books coming soon in both South Asian languages and in English. The books are all designed to empower young minds and encourage their love for learning. Through Mistry-Patel’s experience in the education sector, her experience over the years has allowed her to create resources with neurodivergent students in mind. Keep up-to-date with the latest resources, services and books created by Academic Achievements Ltd on their socials.

Connect with the Movement

Platform	Details
Website	www.academicachievements.co.uk
Instagram	@academicachievementsltd,@author_divyamistrypatel
Facebook	Academic Achievements
Educational Inquiries	help@academicachievements.co.uk info@academicachievements.co.uk

Disclaimer

This article was authored, developed, and distributed by Evrima Chicago, LLC, serving as the official editorial and media representative for Divya Mistry-Patel, founder of Academic Achievements Ltd and author of Mari Rang Be Range Biladi. This content is released for educational, cultural, and journalistic purposes.

• Evrima Chicago officially represents Divya Mistry-Patel for all media, publicity, and syndication matters related to this article and affiliated literary works.

• The views, insights, and commentary expressed herein are based on interviews, verified statements, and publicly available materials, and reflect the intent to inform and inspire discourse on bilingual education and cultural preservation.

• This article is not legal advice, nor does it reflect the views of any government agency or institutional partner mentioned.

• All statistics, studies, and expert quotes referenced are cited in the Sources & Citations section at the end of this publication.

• Reproduction, excerpting, or redistribution of this content must credit both the author and Evrima Chicago, LLC as the originating editorial source.

• Educators, community leaders, librarians, and institutions are encouraged to use this article as part of broader conversations on multilingualism, diversity, and inclusive learning.

Media & PR Contact

Dan Wasserman
Head of Media & Public Affairs
PR@EvrimaChicago.com
+1 (909) 326-0347
Evrima Chicago – Editorial Syndication Bureau

Sources & Citations

Source	Details
UNESCO Language Endangerment Report	https://www.unesco.org/en/days/mother-language
University of Chicago Study on Bilingualism	Bialystok, E., & Barac, R. (2012). Executive Function and Cognitive Flexibility in Bilingual Children
Cooperative Children’s Book Center 2022 Report	https://ccbc.education.wisc.edu/literature-resources/ccbc-diversity-statistics/
UK Gov Report on Children’s Language Usage	Department for Education, UK (2020)
Dr. Ananya Sharma Quote	Language and Identity Studies, Delhi University Symposium, 2023

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire

New index inclusion aligns with company’s domestic growth strategy, including new facility and increased hiring

ORLANDO, FLORIDA / ACCESS Newswire / June 30, 2025 / Unusual Machines, Inc. (NYSE American:UMAC), a leader in drone technology and component manufacturing, announced its inclusion in the Russell Microcap® Index, effective today. The addition reflects the company’s accelerating growth and aligns with its ongoing strategy to scale U.S. operations and strengthen domestic manufacturing capabilities.

“Being added to the Russell Microcap Index marks an important milestone in our growth journey,” said CEO Allan Evans. “It reflects increasing visibility in the market and underscores the strategic steps we’re taking to advance a strong, U.S.-based foundation for long-term success.”

In parallel, Unusual Machines is expanding its U.S.-based workforce to support this next phase of growth, with hiring underway across engineering, operations, and manufacturing roles.

“As we scale, we’re focused on more than just infrastructure-we’re building the team that will power our next chapter,” Evans added. “We’re making targeted investments in areas that drive long-term value, while maintaining a measured approach to capital allocation as we work toward achieving cash flow positivity over the next four to six quarters.”

The announcement follows the company’s recent lease of a 17,000-square-foot drone motor production facility in Orlando, Florida-part of a broader strategy to localize manufacturing, enhance cost efficiency through tariff advantages, and better control quality and lead times. The company’s dual-sourcing approach will allow it to offer both U.S.-made and globally sourced motor variants, providing flexibility to meet regulatory requirements and evolving customer preferences.

Please visit www.unusualmachines.com/careers for the company’s latest job opportunities.

About the Russell Microcap® Index

The Russell Microcap Index includes the smallest 1,000 securities in the Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. Inclusion in the index means Unusual Machines will be automatically added to relevant growth and value style indexes used by institutional investors and index funds.

About Unusual Machines

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032.

For more information, visit www.unusualmachines.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements include: our expectation that our targeted investments will drive long-term value and our expectation that we will achieve cash flow positivity over the next four to six quarters. The results expected by some, or all of these forward-looking statements may not occur. Factors that affect our ability to achieve these results include the impact of and duration of the tariff policies, including (i) Also see the Risk Factors contained in our Form 10-Q, filed with the SEC on May 8, 2025, Prospectus Supplement filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025 and in our Form 10-K for the year ended December 31, 2024. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Any forward-looking statement made by us herein speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

CS Investor Relations
investors@unusualmachines.com
917-633-8980

Media Contact:

media@unusualmachines.com

SOURCE: Unusual Machines, Inc.

View the original press release on ACCESS Newswire

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors

Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection

IND-enabling studies underway, with Phase I study initiation expected in 2Q26

Webcast and conference call to be held today at 4:30 pm ET

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration.

“We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,” said Dinesh V. Patel, PhD, President and CEO of Protagonist. “PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.”

PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026.

“While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,” added Dr. Patel. “We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.”

Conference Call and Webcast Details
The dial-in numbers for Protagonist’s investor update on Monday, June 30^th at 4:30 pm ET are:

US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335

The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage following the event.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) which is licensed to J&J Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra’s joint discovery by Protagonist and JNJ scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as “anticipate,” “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading “Risk Factors” contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext. 1

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

Glass Lewis recommends FOR all five Askeladden Nominees, citing “detailed, coherent, and realistic strategy” and “well-rounded skills and expertise”

Glass Lewis believes “all directors who served at the time of the MTEX acquisition… should be replaced”

AstroNova shares initially soar over 25% (as of 2 PM ET) on news of CEO Greg Woods’ resignation, validating Askeladden’s analysis

Askeladden proposes immediate and constructive resolution of the proxy contest

FORT WORTH, TX / ACCESS Newswire / June 30, 2025 / Dear AstroNova shareholders:

We are pleased to announce that leading independent proxy advisory firm Glass Lewis Inc. has concluded that there is a compelling case for change at AstroNova and recommended AstroNova shareholders vote for all five Askeladden nominees on the GOLD card. We also comment on CEO Greg Woods’ resignation in light of these and other recent developments, and announce our intention to propose a settlement offer to the Board.

Glass Lewis Endorses Askeladden

Glass Lewis completely endorsed Askeladden’s case for change. Glass Lewis* concludes “AstroNova’s TSR [total shareholder return] compared to all peers…suffered the largest value destruction, by a significant margin, over the 1-year period, directly correlating with the Company’s acquisition of MTEX.”

Consequently, GL recommends “all directors who served at the time of the MTEX acquisition…should be replaced, as they should be held accountable for inadequate due diligence, failure to timely identify operational and cultural issues, meaningful destruction of shareholder value, and poor board oversight.”

Glass Lewis also agrees with Askeladden’s plan for the company: “we are convinced that such plan encompasses a detailed, coherent, and realistic strategy to improve the Company’s financial and operational situation going forward, also demonstrating the Dissident’s thorough understanding of the Company’s current weaknesses as well as the industry’s trends and dynamics.”

Finally, Glass Lewis expressed confidence that the Askeladden director candidates can execute that plan: “[W]e are confident the [Askeladden] Nominees will be able to execute the … plan, thanks to their well-rounded set of skills and expertise, including but not limited to M&A and integration, and business turnaround.”

Greg Woods Resigns

ALOT shareholders learned this morning that Greg Woods resigned as CEO and Board member, merely weeks after the Board repeatedly expressed their complete support for Woods and highlighted his knowledge and customer relationships. Board member Darius Nevin will become interim CEO, as the Board undertakes a search for a new CEO. As of roughly 2 PM E.T., AstroNova shares initially soared over 25% from the prior close, as demonstrated in the chart below from Bloomberg (created at 1:44 P.M. ET). We believe this strongly positive market response to Mr. Woods’ resignation validates our published analysis.

Our Interest in Constructive Change

In March, we repeatedly requested the company to work with us privately to address our concerns and forestall the cost and distraction of a proxy contest, yet the company chose to ignore our concerns for nearly three months. Askeladden’s preference has always been to put ALOT shareholders first and resolve the pending proxy contest constructively.

With the shareholder meeting postponed once again, which means even more time, effort, and cost will be expended by both parties if this process continues, we believe a collaborative and amicable resolution is in the best interests of all AstroNova shareholders. By the close of business tomorrow, July 1^st, we intend to deliver a concrete proposal to AstroNova’s Board that will protect shareholders’ interests by adding fresh, independent perspectives to the Board, an imperative now endorsed by both ISS and Glass Lewis. We sincerely hope that our next news release can be jointly published with AstroNova, announcing an end to this proxy contest.

We believe that a negotiated settlement will enable AstroNova’s refreshed Board to focus on rapidly restoring and maximizing AstroNova’s shareholder value. The company’s most immediate priority is the search process for a new CEO. We believe independent oversight is critical, and that our extensive research and industry contacts, including multiple C-level print-industry executives, will serve the company well as it works through this process.

We encourage fellow shareholders and interested parties to visit askeladdencapital.com/astronova for additional information including Askeladden’s published analysis and presentation.

Sincerely,

Samir Patel
samir@askeladdencapital.com
(682) 553-8302

This filing, and future filings, will also be made available to shareholders after dissemination on EDGAR via our website: https://www.askeladdencapital.com/astronova/ These documents will also be available at no cost at www.sec.gov.

*Permission to use quotations from the Glass Lewis report was neither sought nor obtained.

Samir Patel, Askeladden Capital Management LLC, Jeff Sands, Shawn Kravetz, Ryan Oviatt and Boyd Roberts (collectively the “Participants”) filed a definitive proxy statement and accompanying proxy card with the SEC on May 20, 2025, as amended on May 21, 2025, to be used in soliciting proxies in connection with the 2025 annual meeting of shareholders (the “Annual Meeting”) of AstroNova, Inc. (the “Company”). All shareholders of the Company are advised to read the Proxy Statement and other documents related to the solicitation of proxies, each in connection with the Annual Meeting, by the Participants, as they contain important information, including additional information related to the Participants, including a description of their direct or indirect interests by security holdings or otherwise. The Proxy Statement and an accompanying GOLD proxy card will be furnished to some or all of the Company’s stockholders and is, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov, or by contacting Samir Patel at 1452 Hughes Road, Suite 200 #582, Grapevine, TX, 76051.

SOURCE: Askeladden Capital Management LLC

View the original press release on ACCESS Newswire

NEW CANAAN, CT / ACCESS Newswire / June 30, 2025 / Network-1 Technologies, Inc. (NYSE:NTIP) announced today that it has initiated patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. (collectively, “Samsung”) in the United States District Court for the Eastern District of Texas for infringement of U.S. Patent No. 11,233,780, U.S. Patent No. 11.916,893, U.S. Patent No. 12,207,094, U.S. Patent No. 12,166,869, U.S. Patent No.11,606,204, and U.S. Patent No. 11.973,864 (collectively, the “Patents-in-Suit”).

The lawsuit alleges that Samsung infringes the Patents-in-Suit by supporting certain eSIM (embedded Subscriber Identification Module) and 5G technologies in its mobile devices, including its Galaxy smartphones, watches and tablets (the “Accused Products”). The Accused Products operate consistent with certain GSMA and ETSI industry standards.

The Patents-in-Suit are part of the M2M/IoT patent portfolio acquired by Network-1 in December 2017 (the “M2M/IoT Patent Portfolio”). The M2M/IoT Patent Portfolio relates to, among other things, enabling technology for authenticating and using eSIM technology in Internet of Things (“IoT”), Machine-to-Machine, and other mobile devices, including smartphones, tablets, watches, computers and automobiles. Patents in the M2M/IoT Patent Portfolio also relate to enabling technologies for 5G network authentication used in consumer and M2M devices (including smartphones), and the latest available Internet transport layer security solutions.

A study by the Trusted Connectivity Alliance (TCA) found that 2024 was a landmark year of growth across the global eSIM ecosystem during which the volume of eSIM device shipments surpassed 500 million units with eSIM profile downloads increasing by 56%.

Network-1’s M2M/IoT Patent Portfolio includes forty-one (41) issued U.S. patents (and 6 pending applications), plus fifteen (15) issued non-U.S. patents. The patent terms of the MTM/IoT Patent Portfolio are currently expected to extend until 2033-2034. Network-1 has been developing the portfolio since its acquisition and anticipates further issuances of additional claims.

The M2M/IoT Patent Portfolio is available for licensing to firms that make use of the technologies covered by its patents, including eSIM and 5G technologies covered by the relevant GSMA and ETSI standards, as implemented in Internet of Things and M2M products as well as devices utilizing 5G.

ABOUT NETWORK-1 TECHNOLOGIES, INC.

Network-1 Technologies, Inc. is engaged in the acquisition, development, licensing and protection of its intellectual property and proprietary technologies. Network-1 works with inventors and patent owners to assist in the development and monetization of their patented technologies. Network-1 currently owns one hundred fourteen (114) U.S. patents and sixteen (16) international patents covering various technologies, including enabling technology for authenticating and using eSIM technology in Internet of Things (“IoT”), certain advanced technologies related to high frequency trading, technologies relating to document stream operating systems and the identification of media content and enabling technology to support, among other things, the interoperability of smart home IT devices. Network-1’s current strategy includes efforts to monetize four patent portfolios (the M2M/IoT, HFT, Cox and Smart Home portfolios). Network-1’s strategy is to focus on acquiring and investing in high quality patents which management believes have the potential to generate significant licensing opportunities as Network-1 has achieved with respect to its Remote Power Patent and Mirror Worlds Patent Portfolio. Network-1’s Remote Power Patent has generated licensing revenue in excess of $188,000,000 from May 2007 through March 31, 2025. Network-1 has achieved licensing and other revenue of $47,150,000 through March 31, 2025 with respect to its Mirror Worlds Patent Portfolio.

This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements address future events and conditions concerning Network-1’s business plans. Such statements are subject to a number of risk factors and uncertainties as disclosed in the Network-1’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 28, 2025 and its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 including, among others, Network-1’s uncertain revenue from licensing its intellectual property, uncertainty as to the outcome of pending litigation involving Network-1’s HFT Patent Portfolio, whether Network-1 will be successful in its appeal to the Federal Circuit of the District Court judgment of non-infringement dismissing Network-1’s litigation against Google and YouTube involving certain patents within our Cox Patent Portfolio, the ability of Network-1 to successfully execute its strategy to acquire or make investments in high quality patents with significant licensing opportunities, Network-1’s ability to achieve revenue and profits from its Cox Patent Portfolio, M2M/IoT Patent Portfolio, HFT Patent Portfolio and Smart Home Portfolio, as well as a successful outcome on its investment in ILiAD Biotechnologies, LLC or other intellectual property it may acquire or finance in the future, the ability of Network-1 to enter into additional license agreements, uncertainty as to whether cash dividends will continue be paid, Network-1’s ability to enter into strategic relationships with third parties to license or otherwise monetize their intellectual property, , the risk in the future of Network-1 being classified as a Personal Holding Company which may result in Network-1 issuing a special cash dividend to its stockholders, future economic conditions and technology changes and legislative, regulatory and competitive developments. Except as otherwise required to be disclosed in periodic reports, Network-1 expressly disclaims any future obligation or undertaking to update or revise any forward-looking statement contained herein.

Corey M. Horowitz, Chairman and CEO
Network-1 Technologies, Inc.
917-692-0000

SOURCE: Network-1 Technologies, Inc.

View the original press release on ACCESS Newswire

PLANO, TX / ACCESS Newswire / June 30, 2025 / Think Power Solutions, a leading provider of tech-enabled utility infrastructure and field services, announces a key leadership transition as Daniel Helman assumes the role of Chief Executive Officer, effective immediately. This follows the departure of Founder and CEO Hari Vasudevan, whose 12 years of visionary leadership have helped shape the company into a trusted partner across the electric utilities industry.

Hari Vasudevan remains an active investor in Think Power Solutions, continuing to support the company’s long-term mission.

Daniel Helman brings more than 35 years of operational experience to the role, including 20 years in the power generation and construction industry. Most recently, Dan served as Chief Operating Officer of Think Power Solutions for two years, preceded by his tenure as Environmental, Health, and Safety Leader. His deep operational expertise, unwavering commitment to safety, and passion for innovation make him exceptionally well-suited to lead Think Power into its next phase of growth.

“I’m honored to lead this outstanding team into the next chapter,” said Daniel Helman. “We’ll continue to build on the strong foundation Hari created and drive new levels of operational excellence and client success.”

Dan’s appointment signals continued momentum toward excellence, innovation, and customer-centric service delivery. Under his leadership, Think Power Solutions will remain focused on delivering exceptional value, safety, and performance across its client portfolio.

“We are excited to welcome Dan as our new CEO,” said Lawrence LeBlanc, Chief Financial Officer at Think Power Solutions. “His proven leadership, operational discipline, and alignment with our values position him to guide the company into a dynamic and impactful future.”

To learn more about Dan Helman, visit his LinkedIn.

About Think Power Solutions
Think Power Solutions is a leading provider of AI-enabled utility infrastructure solutions. The company partners with many of the nation’s largest investor-owned and cooperative utilities. Known for its operational excellence, innovative technology, and industry-leading safety record, Think Power has earned a reputation as a trusted partner in the utility sector. With a culture grounded in innovation, excellence, strong employee engagement, and entrepreneurial spirit, Think Power Solutions continues to attract top-tier talent and deliver high-performance services and products that support the evolving needs of the utility industry.

For more information visit: https://www.thinkpowersolutions.com Follow us on LinkedIn, X, and Facebook.

Sayantan Dasgupta
Director Marketing – Brand & Content
Think Power Solutions
sayantan.dasgupta@thinkpowersolutions.com

SOURCE: Think Power Solutions

View the original press release on ACCESS Newswire

– Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth –

STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (ADCL), a business that provides molecular and genetic testing services, effective June 27, 2025.

The Company’s actions are intended to substantially reduce its operating costs and concentrate resources behind LineaRx to: (i) enhance the capabilities of LineaRx’s LineaDNA™ and LineaIVT™ platforms while scaling commercial adoption, (ii) expand its service offerings; and (iii) pursue strategic partnerships. LineaRx is advancing platform technologies for the enzymatic manufacture of synthetic DNA and associated enzymes used in the production of DNA- and RNA-based medicines.

“We believe these strategic decisions enable us to set business priorities, funds, and management attention behind LineaRx as our highest-conviction growth opportunity, while also positioning the company for greater operational efficiency, sharper execution, and clearer industry and investment theses,” stated Judy Murrah, chairperson, president, and CEO.

Added Clay Shorrock, president of LineaRx, “Demand for enzymatically produced DNA is accelerating, driven by the expanding field of genetic medicines. Our LineaDNA and LineaIVT platforms are well-positioned to meet this need, and we are aligning all resources towards customer acquisition, expanding market penetration, and scaling efficiently.”

Corporate Updates

• The workforce reduction represents an approximately 27% reduction in headcount, equating to a projected 23% reduction in annual payroll costs, excluding payroll expenses incurred as a result of the previously announced retirement of the Company’s former Chairman and CEO. The projected annual payroll savings is expected to be partially offset by approximately $300 thousand in one-time charges related to the workforce reduction, primarily for separation benefits.

• The Company expects to incur the majority of workforce reduction-related costs by the end of the fourth quarter of fiscal 2025 (quarter ending September 30, 2025), excluding expenses associated with the retirement of the Company’s former Chairman and CEO.

• Since initiating its strategic restructuring in December 2024, Applied DNA has exited non-core operations and reduced headcount by 39% for a projected 31% reduction in annual payroll expenses as compared to the fiscal year ended September 30, 2024, excluding costs related to the retirement of the Company’s former Chairman and CEO. In addition to the actions reported in this press release, the Company exited its DNA Tagging and Security Products and Services business segment in February 2025 and undertook a workforce reduction of approximately 20% of the then-total headcount, primarily related to employees associated with this segment.

• The Company ended May 31, 2025, with approximately $4.8 million in cash and cash equivalents.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the Company is commercializing its LineaDNA and LineaIVT platforms to enable the manufacture of the next generation of nucleic acid-based therapies.

About the LineaDNA™ and LineaIVT™ Platforms

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the LineaDNA platform produces high-fidelity DNA that is free of adventitious sequences, rapidly scalable, and easily amenable to chemical modification. It can generate DNA from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality grades.

The LineaIVT platform offers a streamlined solution for mRNA production via integration of DNA IVT template manufacturing from the LineaDNA platform with the Company’s proprietary LineaRNAP™ enzyme. The platform’s unique integrated approach bypasses plasmid DNA as a starting material, prevents or reduces double-stranded RNA (dsRNA) contamination, and simplifies mRNA production workflows.

Visit adnas.com for more information. Follow us on X and LinkedIn.

Forward-Looking Statements

The statements made by Applied DNA Sciences in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company’s expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its LineaDNA™ and LineaIVT™ platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to the Company’s history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future ability to continue its listing on the Nasdaq Capital Market, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, as well as various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Applied DNA Sciences Contact:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / June 30, 2025 / GPO Plus, Inc. (OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model, is proud to share this shareholder update highlighting key achievements and unveiling strategic initiatives designed to generate recurring revenue and fuel sustainable, long-term growth.

Dear Shareholders,

Wow, we are genuinely thrilled about the incredible momentum and extraordinary achievements here at GPOX! In December, we announced several major initiatives, and I am ecstatic about the progress we are making; our future couldn’t look brighter!

Massive heartfelt thanks go out to our shareholders, investors, partners, vendors, and especially our dedicated team. Your unwavering support and enthusiasm fuel our growth, enabling us to execute our strategic vision and consistently achieve remarkable results.

Here’s why you should be excited:

• GPOX is laser-focused on driving aggressive revenue growth.
  Every strategy and initiative is designed to expand our market reach, enhance profitability, and generate tangible value for our shareholders.

• We have been executing our vision extraordinarily well.
  We consistently surpass internal targets, manage resources effectively, and deliver operational excellence across every aspect of our business.

• We’re poised for continued success.
  Exciting initiatives are underway, and our future holds even greater potential. We’re delighted to have you with us on this journey!

Every initiative we’re working on is engineered to enhance profitability and dramatically amplify shareholder value. We’re not just dreaming big; we’re executing relentlessly!

New Sales Initiatives

• DISTRO+ Cash & Carry:
  As highlighted in our recent press releases, this initiative provides retailers with immediate access to our products, streamlining the sales process, reducing lead times, and strengthening retailer relationships through convenience and reliability.

• Call Centers:
  As previously announced, we’ve launched our call center operations to effectively penetrate new markets and regions that are currently underserved, significantly broadening our geographic and revenue footprint nationally.

• Direct Sales Team:
  Since our announcement, our dedicated sales representatives have been engaging retailers personally, building stronger relationships, enhancing customer loyalty, and driving long-term revenue growth.

• Direct-to-Consumer (DTC):
  Later this year, we will launch dedicated websites for our GPOXBrands, directly connecting with consumers and enhancing our brand visibility and profitability.

Q3 Results – Results speak louder than words

• Gross Revenues: Up around 11% year-to-date, reflecting successful strategic initiatives and significant market penetration.

• Operational Efficiency:Operating expenses have been reduced by nearly 30%, showcasing our financial discipline and operational excellence.

• Margin Improvement:Gross margins improved dramatically from 15% to 28%, reflecting the successful optimization and management of resources.

AI + PRISM+ Integration

Strategically integrating AI across our operations, we’re significantly enhancing human productivity, enabling our talented team to focus on high-impact activities. This innovative approach boosts operational efficiency without having to hire additional team members or reduce employment.

Lubbock Regional Hub Upgrade

• We’ve successfully completed a climate-controlled upgrade to our Lubbock facility, enabling us to expand our product lines and optimize our operations, positioning us for substantial future growth.

• We are now working on setting up the Lubbock DISTRO+ Cash + Carry, scheduled to launch this fall.

Las Vegas Warehouse Expansion

• Warehouse Operations:
  We’re actively recruiting and training a dedicated warehouse team to manage our growing distribution capabilities efficiently.

• DISTRO+ Cash & Carry Launch:
  Our highly anticipated Las Vegas DISTRO+ Cash + Carry operation is set to launch this fall, substantially elevating our local market presence and distribution capabilities.

• Expanded Warehouse Facility:
  We’ve secured additional warehouse space, which will significantly improve logistics, inventory management, and customer service.

Las Vegas Call Center Launch: Phase 1 Initiated

• Experienced Call Center Leadership hired.
  We’ve brought on an experienced leader to drive operational excellence within our call centers and general sales.

• Rapid Team Expansion.
  A proactive growth strategy demonstrating confidence in this channel’s revenue-generating capabilities.

• Phase 2 will add additional seats in a second Las Vegas location.
  Planning is underway to launch a second call center. This will add up to 12 additional positions. Expanding our capacity significantly boosts sales potential and market coverage.

SurgePays Strategic Partnership

We’ve effectively initiated a strategic collaboration with SurgePays (NASDAQ:SURG), significantly enhancing our market penetration and optimizing our sales effectiveness through combined resources and expertise. We announced the desire to build a dedicated outbound sales team for GPOX to bring our high-demand product lines to their retail network.

New Product Categories

We’re actively expanding our product offerings, strategically aligning new, high-demand categories with our distribution model to enhance profitability and market opportunities. This will provide lucrative opportunities that are specifically aligned with our efficient DISTRO+ Cash + Carry b2b business and distribution model.

Las Vegas Field Team: G-Force

• We recently announced the deployment of our GPOXField Operations + Retail Channel Engagement sales team, “G-FORCE” in Las Vegas to drive new retail account growth and deepen market penetration.

• Our dynamic G-Force team is establishing ongoing relationships with local retailers, engaging with them regularly to ensure a strong brand presence, outstanding customer service, and robust revenue growth.

• With the early success, we will likely deploy G-FORCE into other markets as well.

DISTRO+ Wholesale Portal

We’ve launched an efficient and streamlined portal to simplify retailer interactions, significantly enhance ordering processes, and rapidly introduce new products, thereby greatly enhancing operational efficiency.

---

GPOX has shifted decisively from the foundational build-out of its DSD infrastructure to executing a nationwide growth strategy. With a longer-term objective of scaling to over 20,000 retail partners, each generating more than $5,000 per month in sales nationwide.

Once again, thank you for your ongoing support and enthusiasm as we continue to execute these exciting initiatives. Together, we’re building a truly remarkable future!

Best,

Brett H. Pojunis
CEO, GPO Plus, Inc.

---

For more information on GPOX’s growth initiatives, visit GPOPlus.com.

Connect with us on social media to view live video updates, content, and general information about GPOX: https://gpoplus.com/social.

---

About GPOPlus+ (GPOX)
GPOX is an AI-powered Distributor revolutionizing the future of distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model. Our goal is clear and ambitious: “to build the largest nationwide DSD distribution company servicing gas stations, convenience stores, and beyond.” Our technology-driven AI network, featuring strategically placed Regional Hubs and Mini Hubs, is designed to optimize efficiency and maximize reach. Central to our operations is our in-house AI technology platform, PRISM+. Designed to streamline the distribution process, PRISM+ supports efficient delivery, inventory management, data analytics, and overall operational excellence, enabling us to reliably and effectively meet the dynamic needs of our partners. Our mission is to consolidate the fragmented market segment managed by numerous regional vendors. Our dedication to excellence is evident in our product selection process, where we align offerings with consumer demand and partner with top-tier vendors and brands, ensuring our portfolio remains diverse and highly profitable. For more information, please visit www.GPOPlus.com.

---

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company’s need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company’s products, and other risks that are detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as “may,” “will,” “can” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential,” and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company’s actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:

GPOX Shareholder Success Team:
Brett H. Pojunis, CEO
Email: ir@gpoplus.com
Shareholder’s Line: 855.935.GPOX (4769)

SOURCE: GPO Plus, Inc.

View the original press release on ACCESS Newswire

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%

The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar’s intestinal failure products, resulting in non-dilutive funding for Jaguar

SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi.

As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, initial proof-of-concept results from this study show that crofelemer, Jaguar’s novel plant-based anti-secretory prescription drug, reduced the required TPN and supplementary intravenous fluids in the first participating MVID patient by up to 27% and in the first participating SBS-IF patient by up to 12.5%. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output – an indicator of improved nutrient oral absorption.

“We’re very pleased to report that the second pediatric SBS-IF patient participating in this IIT exhibited a similar response for TPN reduction, further exemplifying that crofelemer’s paradigm-shifting antisecretory mechanism of action may have the potential to provide a novel therapeutic option to modify disease progression due to the reductions in TPN and associated comorbidities in MVID and SBS-IF patients and improve their quality of life,” said Lisa Conte, Jaguar’s Founder and CEO. “This SBS-IF patient was administered the highest dose of crofelemer provided for in the approved protocol for the IIT, with no resulting safety issues.”

Per the IIT protocol, as announced, the initial pediatric MVID patient participating in the study was taken off crofelemer after 12 weeks of treatment for an intended period of 30 days. However, after just 8 days, the patient’s parents requested reinitiation of crofelemer dosing, as the patient’s symptoms worsened – evidenced by increased stool output and decreased urine output – and the patient was restarted on daily treatment with crofelemer. The initial pediatric SBS-IF patient participating in the study also had crofelemer withdrawn per the protocol after 12 weeks. This patient then exhibited a relapse of symptoms and was put back on daily treatment with crofelemer, and has since been maintaining a significant TPN reduction. Jaguar plans to continue supplying crofelemer to Dr. Mohamad Miqdady, the principal investigator for this IIT, for the patients participating in this study for as long as Dr. Miqdady feels is medically necessary.

Dr. Miqdady has submitted initial proof-of-concept data from the ongoing IIT in Abu Dhabi for all three above-referenced patients to a major international pediatric gastroenterological conference for consideration for presentation.

Jaguar, through Jaguar family companies Napo and Napo Therapeutics, is currently supporting two independent proof-of-concept IITs, and conducting two placebo-controlled Phase 2 studies, of crofelemer in patients with intestinal failure due to MVID and SBS-IF in the United States, European Union, and/or Middle East/North Africa regions.

Completion of Napo’s randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.

“Our strategy is to seek business development partnerships for license rights for development and commercialization of Jaguar’s intestinal failure products – with the goal of generating non-dilutive funding for Jaguar,” said Conte. “Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the ongoing IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval.”

Based on the initial findings of the ongoing IIT in Abu Dhabi, crofelemer’s paradigm-shifting antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in patients with intestinal failure due to MVID and short bowel syndrome. The observed groundbreaking TPN reduction is particularly compelling for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management and for which no approved drug treatments exist, or any potential approach to reduce TPN.

The initial proof-of-concept data in MVID supports crofelemer’s potential inclusion in the European Medicines Agency’s (EMA) PRIME program that may accelerate regulatory approval pathways in the EU for this indication. This data may also support qualification of crofelemer for the FDA’s Breakthrough Therapy program for expedited regulatory approval in the US. Additional proof-of-concept results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions.

The IIT in Abu Dhabi is being conducted by Dr. Miqdady at Sheikh Khalifa Medical City (SKMC), a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi. Dr. Miqdady, a recognized leader in pediatric gastroenterology, serves as the Chief of Pediatric Gastroenterology, Hepatology and Nutrition at SKMC. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi, and also serves as a member of Napo’s Scientific Advisory Board. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children’s Hospital in Houston.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood,” of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative(ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health/

Napo Pharmaceuticals, visit www.napopharma.com Napo Therapeutics, visit napotherapeutics.com Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that completion of Napo’s Phase 2 study of crofelemer in pediatric MVID patients will occur mid-2026, Jaguar’s expectation that its strategy of seeking business development partnerships for license rights for development and commercialization of Jaguar’s intestinal failure products may support generation of non-dilutive funding for Jaguar, Jaguar’s expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval of crofelemer for MVID, Jaguar’s expectation that crofelemer’s mechanism of action may have the potential to provide a novel therapeutic option to reduce TPN and associated complications, including liver, renal, and cognitive deficits, as well as infections from IV infusion, in pediatric MVID and SBS-IF patients, Jaguar’s expectation that proof-of-concept data in MVID may support crofelemer’s potential inclusion in the EMA’s PRIME program for expediated and assisted regulatory approval and in the FDA’s Breakthrough Therapy program for expedited regulatory approval in the US, Jaguar’s expectation that additional proof-of-concept results from IITs will be available throughout 2025, and Jaguar’s expectation that published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for MVID and SBS-IF. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire